ADHD and Parkinson's disease: unraveling the link and implications for early intervention
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2025.119462 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Zorian Radomyslsky und 3 weiteren Autor:innen. Beteiligte Einrichtung: Maccabi healthcare services, Tel Aviv-Jaffa 6812509, Israel; Department of Health system management, Ariel University, Ariel 40700, Israel; School of…. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Parkinson Disease, Early Medical Intervention. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Attention deficit/hyperactivity disorder (ADHD) and Parkinson's disease (PD) are neurodevelopmental and neurodegenerative conditions respectively, involving alterations in dopamine signaling pathways. Emerging evidence suggests ADHD may be a potential risk factor for earlier PD onset. However, rigorous investigation of this association is still lacking. AIM: To examine the association between ADHD history and subsequent development of PD using a large retrospective cohort study. METHODS: Patients aged ≥50 years were identified from clinician databases between 2010 and 2022 (N = 13,098) and categorized based on ADHD diagnosis. This retrospective cohort study employed Cox proportional hazards models to estimate hazard ratios (HR) for PD according to ADHD history, adjusting for demographic and clinical covariates. Kaplan-Meier survival analysis compared PD-free survival between ADHD and non-ADHD groups, while subgroup analyses explored the effects of ADHD medication use. RESULTS: Individuals with a prior ADHD diagnosis had aa 33 % higher risk of PD (HR = 1.33, 95 % CI 1.12-1.58). Individuals with ADHD exhibited an earlier average age of PD onset. Kaplan-Meier curves demonstrated significantly poorer long-term PD-free survival among individuals with ADHD compared to those without. Subgroup analyses indicated that ADHD medication use did not significantly modify PD risk, as survival trends remained consistent across medicated and non-medicated groups. CONCLUSION: This study provides compelling evidence that ADHD influences PD risk and age of onset. Having ADHD history appears to independently impact long-term PD outcomes. The results highlight a need for tailored monitoring approaches for individuals with ADHD who may face an accelerated PD trajectory. Further research should investigate mechanisms and preventive strategies for high-risk neurodevelopmental populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Maccabi healthcare services, Tel Aviv-Jaffa 6812509, Israel; Department of Health system management, Ariel University, Ariel 40700, Israel; School of Health Sciences, Ariel University, Ariel, Israel.
- Maccabi healthcare services, Tel Aviv-Jaffa 6812509, Israel.
- Nursing Department, The Stanley Steyer School of Health Professions, Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Ramat Aviv, 69978, Israel.
- Nursing Department, The Stanley Steyer School of Health Professions, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Ramat Aviv, 69978, Israel. Electronic address: morsaban1@tauex.tau.ac.il.
Zitieren
APA
Radomyslsky, Z., Kivity, S., Cohen, R., & Saban, M. (2025). ADHD and Parkinson's disease: unraveling the link and implications for early intervention. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.119462
Vancouver
Radomyslsky Z, Kivity S, Cohen R, Saban M. ADHD and Parkinson's disease: unraveling the link and implications for early intervention. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.119462
BibTeX
@article{Radomyslsky2025,
author = {Radomyslsky, Zorian and Kivity, Sara and Cohen, Rut and Saban, Mor},
title = {ADHD and Parkinson's disease: unraveling the link and implications for early intervention},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2025.119462}
}
EUVIMED